JPRN-jRCT2073220005招募中1 期
ADR-001 in Patients with Comprehensive Advanced Chronic Leg Ischemia Phase I Study to Evaluate Safety and Efficacy - ADR-04
furukawa kojiro0 个研究点目标入组 6 人开始时间: 2022年4月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients who have obtained written consent from the patient himself/herself
- •2) Patients who are 18 years of age or older at the time of consent
- •3) Patients with inadequate response to standard drug therapy
- •(Patients treated with beperminogen perplasmin have been administered for 4 weeks and are not eligible to receive beperminogen perplasmin.
- •(Patients judged to have inadequate response)
- •4) Patients with PAD and any of the following clinical symptoms
- •(1) Foot ulcers or ulcers on any of the lower extremities that have existed for at least 2 weeks
- •(2) Gangrene present in the lower extremity or any part of the foot
- •5) Patients whose condition of the target limb at the time of preadministration examination meets all of the following conditions
- •(1) Clinical findings: small area of tissue loss - ischemia of the entire foot with refractory ulceration and localized necrosis.
- •(2) Objective criteria: resting ankle blood pressure less than 60 mmHg and toe blood pressure less than 40 mmHg
排除标准
- •1) Patients with simple venous ulcers, simple wounds, traumatic wounds, acute lower extremity ischemia, ischemic symptoms within 2 weeks, embolism, non-atherosclerotic chronic arterial disease (e.g., vasculitis, Buerger's disease)
- •2) Patients with invasive infections (osteomyelitis, cellulitis, lymphangitis, etc.) in the target limb that are difficult to control with antimicrobial agents
- •3) Patients with deep ulcers with exposed bones, joints or tendons
- •4) Patients with rest pain, ulceration, or necrosis due to spinal cord disease or joint disease
- •5) Patients who have indications for surgical revascularization or endovascular treatment of the target limb, or who have shown improvement in blood flow with these existing treatments.
- •6) Patients who have undergone surgical revascularization or endovascular treatment within 1 month prior to obtaining consent
- •7) Patients with proliferative diabetic retinopathy (untreated proliferative retinopathy, mid- and late-stage proliferative retinopathy) or neovascular type age-related macular degeneration
- •8) Patients with concomitant malignancy or a history of malignancy within 3 years prior to obtaining consent
- •9) Patients with severe cardiac, respiratory, or other comorbidities that make them unsuitable for inclusion in this study, such as the following
- •(1) NYHA Class II-IV congestive heart failure
- •(2) Active coronary artery disease
- •(3) Uncontrolled hypertension
- •(4) Grade 2 or higher arrhythmia in CTCAE ver 5.0, etc.
- •10) Patients with myocardial infarction, cerebral infarction, cerebral hemorrhage, or transient ischemic attack within 3 months prior to obtaining consent
- •11) Patients with allergy or history of allergy to contrast media
- •12) Patients allergic or with a history of allergy to penicillin antibiotics, aminoglycoside antibiotics, or dimethyl sulfoxide (DMSO)
- •13) Patients with concomitant psychiatric disorders deemed to affect obtaining consent
- •14) Patients with drug abuse or alcohol dependence
- •15) Pregnant women, lactating women, women who may be pregnant or men and women who cannot agree to use contraception under the guidance of the investigator or subinvestigator during the study period
- •16) Patients who have participated in other clinical trials such as clinical trials, clinical research and post-marketing clinical trials within 4 weeks prior to obtaining consent
- •17) Other patients deemed ineligible by the investigator (subinvestigator)
研究者
相似试验
进行中（未招募）
2 期
ADR-001-N1Compensated liver cirrhosis (Child-Pugh A)JPRN-jRCT2033210425Terai Shuji9
招募中
2 期
A Phase 2 Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infectioPatients with Severe Pneumonia caused by SARS-CoV-2 infectionJPRN-jRCT2053210023Okawa Sumito20
已完成
1 期
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infection (COVID-19)Patients with Severe Pneumonia caused by SARS-CoV-2 infectionJPRN-jRCT1080225320ROHTO PHARMACEUTICAL CO., LTD.6
招募中
不适用
The efficacy of DAAs against the patients with chronic hepatitis and cirrhosis due to HCVthe patients with chronic hepatitis and cirrhosis due to HCVJPRN-UMIN000018098Shinanomachi Liver Conference300
进行中（未招募）
1 期
An Early Phase Study of DCR-PH1 in Patients with an Inherited Disorder Resulting in Overproduction of OxalatePrimary Hyperoxaluria Type 1MedDRA version: 18.1Level: PTClassification code 10020703Term: HyperoxaluriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-003142-51-NLDicerna Pharmaceuticals, Inc.4